Anthelos KFT

Anthelos mission is to offer a portfolio of specialized research tools and solutions for LNP-related developments and therapies.

Anthelos provides research laboratories and biotech companies with analysis and molecular laboratory testing tools to deliver professional data on Lipid Nanoparticles (LNP) formulation, optimization, characterization, in vitro and in vivo functional tests.

Anthelos expertise in LNPs covers microfluidics design and production with its flexible nanoparticle generating system, LNP characterization, stability tests with its scanning nanoparticle tracking analysis system for tailored LNP formulations to optimize drug delivery for the clients’ specific therapeutic needs.

Efficiency and toxicity studies can be performed by Anthelos in primary immune cells (B-, T-cells), liver and DC cells with plate imaging and FACS analysis. Cell-type specific transfection efficiency analysis of different tissues can be done with confocal fluorescent microscopy. Anthelos applies in vivo imaging by using the company’s custom tailored in vivo imaging system with superior sensitivity for full body imaging, tissue distribution, organ- and cancer-specific targeting projects.

Anthelos is developing novel lipids and lipid additives to enhance LNP effectivity and specific targeting to pancrease, lungs and spleen.

The company has a Medicinal Chemistry Department with highly trained chemists, where LNP ingredients (fatty acid derivatives, additives), novel nucleic acid building blocks (nucleotide analogs, labels, oligonucleotides) and new drug-like molecules can be synthesized. Anthelos also works as a CMO with a licence from University of Colorado, USA to large scale (upto kg) synthesis of modifed nucleotide analogs for therapeutic applications (antisense/exon skipping oligonucleotides).